1. Home
  2. GMED vs MRNA Comparison

GMED vs MRNA Comparison

Compare GMED & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globus Medical Inc.

GMED

Globus Medical Inc.

HOLD

Current Price

$93.99

Market Cap

11.7B

Sector

Health Care

ML Signal

HOLD

Logo Moderna Inc.

MRNA

Moderna Inc.

HOLD

Current Price

$49.79

Market Cap

11.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMED
MRNA
Founded
2003
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7B
11.5B
IPO Year
2012
2018

Fundamental Metrics

Financial Performance
Metric
GMED
MRNA
Price
$93.99
$49.79
Analyst Decision
Buy
Hold
Analyst Count
15
13
Target Price
$95.92
$32.75
AVG Volume (30 Days)
1.5M
11.9M
Earning Date
02-24-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
358.86
N/A
EPS
3.08
N/A
Revenue
$2,769,804,000.00
$2,232,000,000.00
Revenue This Year
$17.65
N/A
Revenue Next Year
$8.37
$3.18
P/E Ratio
$30.18
N/A
Revenue Growth
11.75
N/A
52 Week Low
$51.79
$22.28
52 Week High
$101.40
$45.40

Technical Indicators

Market Signals
Indicator
GMED
MRNA
Relative Strength Index (RSI) 60.13 80.83
Support Level $91.10 $39.21
Resistance Level $94.69 $41.98
Average True Range (ATR) 3.21 2.65
MACD -0.03 1.24
Stochastic Oscillator 52.96 99.84

Price Performance

Historical Comparison
GMED
MRNA

About GMED Globus Medical Inc.

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: